Featured Article

Historical present and potential future PCOS therapies DPP 4 | visionary roundup

Heather Aug 05, 2026

Historical, present and potential future PCOS therapies. DPP

Historical present and potential future PCOS therapies DPP 4
Historical present and potential future PCOS therapies DPP 4

Download scientific diagram | Historical , present and potential future PCOS therapies . DPP-4 , dipeptidyl peptidase-4; GIP, glucose-dependent insulinotropic polypeptide; GLP-1, glucagon-like ...

Table 1 from Effect on Hemoglobin A1c HbA1c and Body Weight After
Table 1 from Effect on Hemoglobin A1c HbA1c and Body Weight After

Conclusion The study reveals global trends in PCOS pharmacotherapy, with a growing focus on metabolic and molecular aspects. Key contributors and emerging therapies highlight the expanding scope and future potential of PCOS treatment research.

The future of PCOS management

Figure 3 from Effect on Hemoglobin A1c HbA1c and Body Weight After
Figure 3 from Effect on Hemoglobin A1c HbA1c and Body Weight After

At present , the treatments such as lifestyle correction, combined oral pills, and anti-insulin therapies along with anti-androgen drugs only have symptomatic roles with no impact on the underlying mechanism associated with PCOS .

We cannot ignore the significance and role of neuroendocrine pathophysiology in PCOS and the potential for the use of treatments which interfere with the neuroendocrine profile [11]. Promising results have emerged in the use of new drugs—NK3R antagonists, or kappa receptor agonists.

PDF Glucose dependent insulinotropic polypeptide and glucagon like
PDF Glucose dependent insulinotropic polypeptide and glucagon like

Modern Polycystic Ovary Syndrome (PCOS) Management

This review discusses these emerging approaches and their potential role in future PCOS management, aiming to transition therapy from short-term symptom control toward sustained ovarian restoration and optimized fertility outcomes.

Newer agents like metformin, GLP-1 receptor agonists, and SGLT-2 inhibitors offer targeted treatments for specific PCOS phenotypes. Precision medicine and bioinformatics have further enhanced the potential for individualized treatments, emphasizing the need for multifaceted management strategies.

PDF Glucose dependent Insulinotropic Polypeptide and Glucagon like
PDF Glucose dependent Insulinotropic Polypeptide and Glucagon like

A Comprehensive Review on Dipeptidyl Peptidase

DPP-4 inhibitors (pleiotropic) in addition to glycemic treatment exhibit pleiotropic characteristics (despite potential cardio- and /or normotensive effects). They have been associated with improved endothelial dysfunction, oxidative stress, and inflammation—all of which are essential in the prevention of diabetic complications.

Drawing on the latest research, this review highlights advanced glycation end products (AGEs), sex hormone-binding globulin (SHBG), and microRNAs (miRNAs) as promising targets for PCOS prevention and treatment. Future research should focus on developing targeted drugs for these molecular pathways, offering new avenues for managing PCOS .

Improving Physicochemical Properties of Biopharmaceutical Drug
Improving Physicochemical Properties of Biopharmaceutical Drug

Polycystic ovary syndrome (PCOS)

Polycystic ovary syndrome ( PCOS ) is a common gynaecological disorder, clinically characterized by chronic anovulation and hyperandrogenism. Despite its high prevalence, no curative treatment exists, and managing the syndrome remains challenging. A strong association between PCOS and metabolic syndrome, particularly insulin resistance, adversely influences fertility, leading to an increased ...

Schematic Depiction of the Pleiotropic Benefits of Dual
Schematic Depiction of the Pleiotropic Benefits of Dual
PDF Mechanisms underlying glucose dependent insulinotropic
PDF Mechanisms underlying glucose dependent insulinotropic
Nephroprotective Properties of the Glucose Dependent Insulinotropic
Nephroprotective Properties of the Glucose Dependent Insulinotropic
The glucose dependent insulinotropic polypeptide GIP regulates body
The glucose dependent insulinotropic polypeptide GIP regulates body
The Incretins and β Cell Health Contrasting Glucose Dependent
The Incretins and β Cell Health Contrasting Glucose Dependent
Glucose dependent insulinotropic peptide
Glucose dependent insulinotropic peptide
Out of stock A brief clinical reference for rough equivalency
Out of stock A brief clinical reference for rough equivalency

Polycystic Ovary Syndrome ( PCOS ) is characterized by a self-perpetuating vicious cycle between insulin resistance (IR) and hyperandrogenism (HA). While lifestyle management remains the internationally recommended first-line treatment, current clinical management, primarily relying on combined oral contraceptives and metformin, offers symptomatic relief or "masking" of the phenotype but ...